摘要
Tet2(tet癌基因家族成员2)是新发现的骨髓恶性肿瘤患者4q24上的肿瘤抑制基因,有发生功能缺失突变的潜能。最近研究表明,在真性红细胞增多症(polycythemia vera,PV)、原发性血小板增多症(essential thrombocy-themia,ET)、骨髓纤维化(myelofibrosis)、系统性肥大细胞增多症(systemic mastocytosis,SM)和骨髓增生异常综合征(myelodysplastic syndrome,MDS)等骨髓恶性疾病中均可发现tet2突变的存在,但tet2在恶性血液系统疾病中的作用仍需要通过大量的前瞻性研究来探索。本文就tet2突变与骨髓增殖性肿瘤、系统性肥大细胞增生症、骨髓增生异常综合征、急性髓系白血病及其它恶性血液病的关系进行了综述。
Tet2 （the 2nd member of tet oncogene family） is a newly discovered antioncogene on the chromosome 4q24 of the patient with malignant myeloma, which has a potential for functional deletion. Recent studies demonstrated that tet2 mutation was found in polyeythemia vera （PV）, essential thrombocythemia （ET）, myelofibrosis, systematic mastocytosis （SM）, and myelodysplastic syndrome （MDS）. However, a great number of perspective researches are still needed for exploring the role of tet2 in the pathogenesis of malignant blood diseases. In this review, the relation of tet2 mutation with myeloproliferative neoplasm, systemic mastocytosis, myelodysplastic syndrome, acute myeloid leukemia and other malignant blood diseases are summarized.
出处
《中国实验血液学杂志》
CAS
CSCD
2010年第4期1096-1100,共5页
Journal of Experimental Hematology
